1357476-69-7

Basic information

• Product Name: 2-ThiazolaMine, 4-Methyl-5-[2-(2,2,2-trifluoro-1,1-diMethylethyl)-4-pyridinyl]-
• Synonyms: 2-ThiazolaMine, 4-Methyl-5-[2-(2,2,2-trifluoro-1,1-diMethylethyl)-4-pyridinyl]-
• CAS NO: 1357476-69-7
• Molecular Formula: C13H14F3N3S
• Molecular Weight: 301.3305696
• Mol File: 1357476-69-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 369.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.297±0.06 g/cm3(Predicted)
• PKA: 3.67±0.10(Predicted)
• CAS DataBase Reference: 2-ThiazolaMine, 4-Methyl-5-[2-(2,2,2-trifluoro-1,1-diMethylethyl)-4-pyridinyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ThiazolaMine, 4-Methyl-5-[2-(2,2,2-trifluoro-1,1-diMethylethyl)-4-pyridinyl]-(1357476-69-7)
• EPA Substance Registry System: 2-ThiazolaMine, 4-Methyl-5-[2-(2,2,2-trifluoro-1,1-diMethylethyl)-4-pyridinyl]-(1357476-69-7)

Safety Data

• Hazardous Substances Data: 1357476-69-7(Hazardous Substances Data)

Usage

General Description

2-ThiazolaMine, 4-Methyl-5-[2-(2,2,2-trifluoro-1,1-diMethylethyl)-4-pyridinyl]- is a chemical compound with a complex and lengthy name. It is a derivative of 2-ThiazolaMine and contains a 4-Methyl-5-[2-(2,2,2-trifluoro-1,1-diMethylethyl)-4-pyridinyl] group. 2-ThiazolaMine, 4-Methyl-5-[2-(2,2,2-trifluoro-1,1-diMethylethyl)-4-pyridinyl]- has potential applications in the pharmaceutical industry and may be used in the synthesis of various drugs or as an intermediate in chemical reactions. Due to its specific structure and properties, it could have potential biological activities or therapeutic effects. However, further research and testing would be needed to fully understand its potential uses and effects.

Upstream product

• 1357476-68-6 C₁₅H₁₆F₃N₃OS 
• 1357476-67-5 4-bromo-2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridine 
• 1357476-66-4 2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4(1H)-one 
• 1357476-64-2 2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4H-pyran-4-one 
• 1163707-53-6 3,3,3-trifluoro-2,2-dimethylpropanoyl chloride 
• 889940-13-0 3,3,3-trifluoro-2,2-dimethylpropanoic acid 

Downstream Products

• 1217486-61-7 alpelisib 

Relevant articles and documents

PI3K INHIBITORS AND USES THEREOF

The development of a new, targeted drug delivery paradigm coupled to improved PI3K inhibitors (e.g., PI3Kα inhibitors) represents a significant advance in cancer therapy. Provided herein are compounds, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds provided herein are PI3K (e.g., PI3Kα) inhibitors and are therefore useful for the treatment and/or prevention of various diseases (e.g., proliferative diseases such as cancer). Also provided herein are nanoparticles and nanogels (e.g., P-selectin targeting nanoparticles) comprising PI3K inhibitors, such a compound described herein. In certain embodiments, a nanoparticle or nanogel described herein encapsulates a compound described herein for targeting delivery to cancer cells or tumors.

Novel synthesis method of PI3K inhibitor Alpelisib

The invention relates to a novel synthesis method of a PI3K inhibitor Alpelisib. According to the synthesis method disclosed by the invention, the target molecule can be synthesized through four stepsof reactions including one-step substitution reaction of starting raw materials, amino protection group removal and two times of halogenation reaction, the total yield is high, the cost is low, and the HPLC purity of the product reaches 99.5% or above.

A CRYSTALLINE FORM OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-(4 -METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYL-ETHYL)-PYRIDIN-4-YL]-THIAZOL-2-YL)-AMIDE AND ITS USE AS PI3K INHIBITOR

The present invention relates to specific solid forms of (S)-pyrrolidine-l,2-dicarboxylic acid 2-amide l-(4-methyI-5-[2-(2,2,2-trifluoro-l,l-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide, (I), and its hydrates and solvates. The present invention further relates to processes for preparing said solid forms, pharmaceutical compositions comprising said solid forms, and methods of using said solid forms and pharmaceutical compositions to treat disease.